CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Income Statement [Abstract]
Net revenues	$ 174,055	$ 154,994	$ 655,353
Cost of revenues	38,929	38,521	166,879
Gross profit	135,126	116,473	488,474
Operating costs and expenses:
Research, development and clinical studies	58,336	53,777	224,544
Sales and marketing	58,357	55,792	240,064
General and administrative	85,853	44,769	177,666
Total operating costs and expenses	202,546	154,338	642,274
Operating income (loss)	(67,420)	(37,865)	(153,800)
Financial income (expenses), net	(1,838)	7,570	17,550
Income (loss) before income tax	(69,258)	(30,295)	(136,250)
Income tax	1,880	4,024	(23)
Net income (loss)	$ (71,138)	$ (34,319)	$ (136,227)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.62)	$ (0.31)	$ (1.22)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.62)	$ (0.31)	$ (1.22)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	114,149,838	110,281,832	111,471,991
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	114,149,838	110,281,832	111,471,991